List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4106555/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: a Kumamoto University Malignancy and Atherosclerosis (KUMA) study. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 290-300.	4.0	53
2	Impact of Statin Therapy on Clinical Outcome in Patients With Coronary Spasm. Journal of the American Heart Association, 2016, 5, .	3.7	51
3	Recurrent Mitral Regurgitation After MitraClip: Predictive Factors, Morphology, and Clinical Implication. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121010895.	3.9	34
4	Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction. Atherosclerosis, 2017, 260, 116-120.	0.8	33
5	Single-wire pressure and flow velocity measurement for quantifying microvascular dysfunction in patients with coronary vasospastic angina. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H478-H484.	3.2	28
6	Prognostic significance of circulating leukocyte subtype counts in patients with coronary artery disease. Atherosclerosis, 2016, 255, 210-216.	0.8	28
7	Safety and Efficacy of Protamine Administration for Prevention of BleedingÂComplications in Patients Undergoing TAVR. JACC: Cardiovascular Interventions, 2020, 13, 1471-1480.	2.9	28
8	Current status and future perspective of structural heart disease intervention. Journal of Cardiology, 2019, 74, 1-12.	1.9	27
9	Risk Factors and Prevalence of Deep Vein Thrombosis After the 2016 Kumamoto Earthquakes. Circulation Journal, 2019, 83, 1342-1348.	1.6	27
10	Impact of aspirin on the prognosis in patients with coronary spasm without significant atherosclerotic stenosis. International Journal of Cardiology, 2016, 220, 328-332.	1.7	26
11	Impact of the Leaflet-to-Annulus Index on Residual Mitral Regurgitation in Patients Undergoing Edge-to-Edge Mitral Repair. JACC: Cardiovascular Interventions, 2019, 12, 2462-2472.	2.9	26
12	Clinical roles of calcium channel blockers in ischemic heart diseases. Hypertension Research, 2017, 40, 423-428.	2.7	25
13	Imaging-guided PCI for event suppression in Japanese acute coronary syndrome patients: community-based observational cohort registry. Cardiovascular Intervention and Therapeutics, 2021, 36, 81-90.	2.3	24
14	Effects of the Mean Amplitude of Glycemic Excursions and Vascular Endothelial Dysfunction on Cardiovascular Events in Nondiabetic Patients With Coronary Artery Disease. Journal of the American Heart Association, 2017, 6, .	3.7	21
15	Temporal trends in coronary intervention strategies and the impact on one-year clinical events: data from a Japanese multi-center real-world cohort study. Cardiovascular Intervention and Therapeutics, 2022, 37, 66-77.	2.3	19
16	Helicobacter pylori Seropositivity in Patients with Interleukin-1 Polymorphisms Is Significantly Associated with ST-Segment Elevation Myocardial Infarction. PLoS ONE, 2016, 11, e0166240.	2.5	19
17	Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation. Thrombosis Research, 2014, 134, 939-944.	1.7	18
18	Percutaneous interventions for mitral and tricuspid heart valve diseases. Cardiovascular Intervention and Therapeutics, 2020, 35, 62-71.	2.3	18

#	Article	IF	CITATIONS
19	Feasibility of Coronary Access in Patients With Acute Coronary Syndrome and Previous TAVR. JACC: Cardiovascular Interventions, 2021, 14, 1578-1590.	2.9	18
20	Prognostic Value of the CHADS <sub>2</sub> Score for Adverse Cardiovascular Events in Coronary Artery Disease Patients Without Atrial Fibrillation—A Multiâ€Center Observational Cohort Study. Journal of the American Heart Association, 2017, 6, .	3.7	17
21	Quantification of Myocardial Extracellular Volume With Planning Computed Tomography for Transcatheter Aortic Valve Replacement to Identify Occult Cardiac Amyloidosis in Patients With Severe Aortic Stenosis. Circulation: Cardiovascular Imaging, 2020, 13, e010358.	2.6	17
22	Prevalence of coronary macro- and micro-vascular dysfunctions after drug-eluting stent implantation without in-stent restenosis. International Journal of Cardiology, 2016, 222, 185-194.	1.7	16
23	Sex differences in the impact of CYP2C19 polymorphisms and low-grade inflammation on coronary microvascular disorder. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H1494-H1500.	3.2	13
24	Relationship between asymptomatic intra-cranial lesions and brachial-ankle pulse wave velocity in coronary artery disease patients without stroke. Hypertension Research, 2017, 40, 392-398.	2.7	13
25	High incidence of coronary spasm after percutaneous coronary interventions. International Journal of Cardiology, 2015, 182, 171-173.	1.7	12
26	The dawn of a new era in onco-cardiology: The Kumamoto Classification. International Journal of Cardiology, 2016, 220, 837-841.	1.7	12
27	Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H1409-H1415.	3.2	12
28	Risk modeling in transcatheter aortic valve replacement remains unsolved: an external validation study in 2946 German patients. Clinical Research in Cardiology, 2021, 110, 368-376.	3.3	12
29	Prognostic impact of cancer history in patients undergoing transcatheter aortic valve implantation. Clinical Research in Cardiology, 2020, 109, 1243-1250.	3.3	11
30	Predictive factors and long-term prognosis of transcatheter aortic valve implantation-associated endocarditis. Clinical Research in Cardiology, 2020, 109, 1165-1176.	3.3	10
31	Patients with both CYP2C19 loss-of-function allele and peripheral endothelial dysfunction are significantly correlated with adverse cardiovascular events following coronary stent implantation. Journal of Cardiology, 2016, 67, 104-109.	1.9	9
32	CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina. IJC Heart and Vasculature, 2017, 15, 15-20.	1.1	9
33	Usefulness of relative apical longitudinal strain index to predict positive <sup>99m</sup> Tcâ€labeled pyrophosphate scintigraphy findings in advancedâ€age patients with suspected transthyretin amyloid cardiomyopathy. Echocardiography, 2020, 37, 1774-1783.	0.9	9
34	Development and assessment of total thrombus-formation analysis system-based bleeding risk model in patients undergoing percutaneous coronary intervention. International Journal of Cardiology, 2021, 325, 121-126.	1.7	9
35	Prognostic significance of liver stiffness assessed by fibrosisâ€4 index in patients with heart failure. ESC Heart Failure, 2021, 8, 3809-3821.	3.1	9
36	Prognostic value of left atrial strain in patients with wildâ€ŧype transthyretin amyloid cardiomyopathy. ESC Heart Failure, 2021, 8, 5316-5326.	3.1	9

#	Article	IF	CITATIONS
37	Impact of left ventricular hypertrophy on impaired coronary microvascular dysfunction. International Journal of Cardiology, 2015, 187, 411-413.	1.7	8
38	Associations between corrected serum calcium and phosphorus levels and outcome in dialysis patients in the Kumamoto Prefecture. Hemodialysis International, 2020, 24, 202-211.	0.9	8
39	Impact of cancer history on clinical outcome in patients undergoing transcatheter edge-to-edge mitral repair. Clinical Research in Cardiology, 2021, 110, 440-450.	3.3	8
40	Impact of esomeprazole on platelet reactivity and clinical outcome according to CYP2C19 genotype in coronary heart disease patients during dual antiplatelet therapy. Thrombosis Research, 2015, 135, 1081-1086.	1.7	7
41	A Randomized, Double-Blind Comparison Study of Royal Jelly to Augment Vascular Endothelial Function in Healthy Volunteers. Journal of Atherosclerosis and Thrombosis, 2022, 29, 1285-1294.	2.0	7
42	Physiological basis of discordance between coronary flow velocity reserve and hyperemic microvascular resistance for evaluating coronary microvascular dysfunction in patients without atherosclerotic obstruction. International Journal of Cardiology, 2015, 201, 535-537.	1.7	6
43	Hemodialysis-related low thrombogenicity measured by total thrombus-formation analysis system in patients undergoing percutaneous coronary intervention Thrombosis Research, 2021, 200, 141-148.	1.7	6
44	Utility of left atrial and ventricular strain for diagnosis of transthyretin amyloid cardiomyopathy in aortic stenosis. ESC Heart Failure, 2022, 9, 1976-1986.	3.1	6
45	Differential impact of peripheral endothelial dysfunction on subsequent cardiovascular events following percutaneous coronary intervention between chronic kidney disease (CKD) and non-CKD patients. Heart and Vessels, 2016, 31, 1038-1044.	1.2	5
46	Early response of right-ventricular function to percutaneous mitral valve repair. Clinical Research in Cardiology, 2022, 111, 859-868.	3.3	5
47	A simple staging system using biomarkers for wildâ€ŧype transthyretin amyloid cardiomyopathy in Japan. ESC Heart Failure, 2022, 9, 1731-1739.	3.1	5
48	The real-world prevalence of cardiovascular events related to coronary spasm after percutaneous coronary intervention. Journal of Cardiology, 2016, 68, 20-28.	1.9	4
49	Changes in the risk factors for coronary spasm. IJC Heart and Vasculature, 2016, 12, 85-87.	1.1	4
50	Clinical characteristics and intravascular ultrasound findings of culprit lesions in elderly patients with acute coronary syndrome. Heart and Vessels, 2016, 31, 341-350.	1.2	4
51	Clinical outcomes of percutaneous coronary intervention for acute coronary syndrome between hospitals with and without onsite cardiac surgery backup. Journal of Cardiology, 2017, 69, 103-109.	1.9	4
52	Distribution of Ankle-Brachial Index among Inpatients with Cardiovascular Disease: Analysis Using the Kumamoto University Hospital Medical Database. Annals of Vascular Diseases, 2016, 9, 22-29.	0.5	4
53	Malnutrition-associated high bleeding risk with low thrombogenicity in patients undergoing percutaneous coronary intervention. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1227-1235.	2.6	4
54	Unprotected left main intervention for surgery-ineligible patients with coronary artery disease—Usefulness of micro-CT images for stent. International Journal of Cardiology, 2016, 221, 385-389.	1.7	3

#	Article	IF	CITATIONS
55	Reduction in thrombogenic activity and thrombocytopenia after transcatheter aortic valve implantation $\hat{a} \in$ "The ATTRACTIVE-TTAS study. IJC Heart and Vasculature, 2019, 23, 100346.	1.1	3
56	Predictive Value of the Platelet-to-Lymphocyte Ratio in Cancer Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: CardioOncology, 2019, 1, 159-169.	4.0	3
57	Combined Percutaneous Therapy for Tricuspid Regurgitation Using the Cardioband and PASCAL System inÂ1ÂProcedure. JACC: Cardiovascular Interventions, 2019, 12, e197-e198.	2.9	3
58	The predictive value of intraprocedural mitral gradient for outcomes after MitraClip and its periâ€interventional dynamics. Echocardiography, 2021, 38, 1115-1124.	0.9	3
59	Prognostic value of right ventricular global longitudinal strain in transthyretin amyloid cardiomyopathy. Journal of Cardiology, 2022, 80, 56-63.	1.9	3
60	Gender differences in impact of vascular endothelial dysfunction on clinical outcome following coronary stenting in patients with coronary heart disease. International Journal of Cardiology, 2014, 177, 723-725.	1.7	2
61	Intraprocedural thrombotic event during coronary intervention depends on CYP2C19 genotype and is a predictor of future clinical event. International Journal of Cardiology, 2015, 187, 231-233.	1.7	2
62	Clinical and morphological presentations of acute coronary syndrome without coronary plaque rupture — An intravascular ultrasound study. International Journal of Cardiology, 2016, 220, 112-115.	1.7	2
63	Helicobacter Pylori-seropositivity along with genetic and environmental factors predicts clinical outcome after acute coronary syndrome. International Journal of Cardiology, 2016, 212, 54-56.	1.7	2
64	Evaluation of Collateral Source Characteristics With 3â€Đimensional Analysis Using Micro–Xâ€Ray Computed Tomography. Journal of the American Heart Association, 2018, 7, .	3.7	2
65	Cytotoxin-associated gene-A-seropositivity and Interleukin-1 polymorphisms influence adverse cardiovascular events. IJC Heart and Vasculature, 2020, 27, 100498.	1.1	2
66	Impact of cerebrovascular comorbidity on prognosis in Japanese patients undergoing PCI: 1-year data from Japanese multicenter registry (KICS). Heart and Vessels, 2022, , 1.	1.2	2
67	Management of intra-aortic balloon counterpulsation by argatroban anticoagulation in a patient with a history of heparin-induced thrombocytopenia. Journal of Cardiology Cases, 2012, 6, e154-e157.	0.5	1
68	Antithrombotic Regimens in Patients Undergoing Transcatheter Aortic Valve Implantation. Circulation Journal, 2017, 81, 308-309.	1.6	1
69	Newer Specific Risk Scores for Outcome After Transcatheter Aortic Valve Replacement. Circulation Journal, 2019, 83, 1630-1632.	1.6	1
70	Association of heart failure duration with clinical outcomes after transcatheter mitral valve repair for functional mitral regurgitation. Catheterization and Cardiovascular Interventions, 2020, 98, E412-E419.	1.7	1
71	Impact of combined baseline and postprocedural troponin values on clinical outcome following the MitraClip procedure. Catheterization and Cardiovascular Interventions, 2020, 96, E735-E743.	1.7	1
72	Successful Aortic Valve-in-Valve Implantation in a Patient With Replaced Aorta, Subclavian Artery Occlusions and Aortic Dissection. Circulation Journal, 2021, 85, 314.	1.6	1

#	Article	IF	CITATIONS
73	A case of human immunodeficiency virus-related heart failure resembling dilated cardiomyopathy but accompanied by high cardiac output. Journal of Cardiology Cases, 2014, 10, 167-170.	0.5	0
74	QRS duration is a risk indicator of adverse outcomes after MitraClip. Catheterization and Cardiovascular Interventions, 2021, 98, E594-E601.	1.7	0
75	Disparities in transcatheter mitral valve repair - Disparities being corrected little by little?. International Journal of Cardiology, 2022, 352, 52-53.	1.7	0